<DOC>
	<DOCNO>NCT01580995</DOCNO>
	<brief_summary>The purpose study examine effect valacyclovir patient chronic hepatitis C , antibodies herpes simplex type 1 infection antibody herpes simplex type 2 infection . Herpes simplex type 1 infection commonly cause cold sore fever blister , also know herpes labialis , person symptom . Valacyclovir medication approve Food Drug administration treat herpes labialis . Valacyclovir approve treat chronic hepatitis C infection . The study take 16 week . Participants assign take either study drug , valacyclovir , sugar pill look exactly like valacyclovir . The researcher patient know medication receiving . Study visit occur every two week take approximately 30-45 minute . All study visit occur G.V . Sonny Montgomery VA Medical Center Jackson , Mississippi .</brief_summary>
	<brief_title>Herpes Simplex Type 1 Suppression Hepatitis C</brief_title>
	<detailed_description>This randomized double-blind placebo-controlled clinical trial evaluate effect 500 mg valacyclovir twice daily HCV viral load HSV-1/HCV co-infected patient seronegative HSV-2 . Potential participant recruit Jackson VAMC viral hepatitis clinic . Eligible individual invite enroll study noncoercive manner . Study personnel obtain full informed consent . Using computer generation randomization scheme , patient randomize 1:1 block 4 receive valacyclovir 500 mg po twice daily match placebo . Patients counsel sign symptom herpes labialis genital herpes complete questionnaire document medical/social history . Venipuncture perform every four week ( i.e. , every follow-up visit ) monitor complete blood cell count , liver function test , serum level hepatitis C RNA Herpeselect IgG HSV-2 ELISA . A de-identified baseline serum sample collect stored VA approve research space future test . At visit , pill-count tolerability medication assess . Patients ask sign symptom genital herpes . Data keep study chart label participant 's cod study number lock office . Information study visit record chart PI RA enter encrypted database secure VA server . Baseline characteristic placebo intervention group compare use appropriate parametric test . HCV viral load log10 transform analyzed use intention treat model .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Chronic hepatitis C infection detectable HCV RNA serum two occasion , 6 month apart Focus HSV2 IgG negative Focus HSV1 IgG positive , use manufacturer 's cutoff Antiherpes immunomodulatory therapy past 30 day , HIV chronic hepatitis B infection , Decompensated liver disease ( ascites , hepatic encephalopathy , coagulopathy , jaundice/icterus ) , Creatinine clearance &lt; 50 ml/min. , Female subject pregnant nursing , Gastrointestinal disorder might result malabsorption valacyclovir , History erythema multiforme major , thrombotic thrombocytopenia purpura hemolytic uremic syndrome , Allergy valacyclovir related drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Chronic hepatitis C infection</keyword>
</DOC>